Rankings
▼
Calendar
URGN (UroGen Pharma Ltd.) Stock Financials & Earnings | Market Cap Arena
URGN
UroGen Pharma Ltd.
Mkt Cap
$927M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$110M
Net Income (TTM)
-$153M
EPS (TTM)
-$3.20
Free Cash Flow (TTM)
-$163M
Gross Margin
88.7%
Op. Margin
-113.7%
Net Margin
-139.8%
FCF Margin
-148.2%
P/S Ratio (TTM)
8.4x
P/E Ratio (TTM)
—
YoY Rev Growth
+21.4%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$17M
$15M
-$22M
Q2 23
$21M
$19M
-$15M
Q3 23
$21M
$18M
-$14M
Q4 23
$24M
$21M
-$15M
Q1 24
$19M
$17M
-$26M
Q2 24
$22M
$20M
-$26M
Q3 24
$25M
$23M
-$18M
Q4 24
$25M
$22M
-$28M
Q1 25
$20M
$18M
-$37M
Q2 25
$24M
$21M
-$41M
Q3 25
$27M
$24M
-$27M
Q4 25
$38M
$35M
-$19M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
13.6x
—
Q2 23
12.8x
—
Q3 23
12.0x
—
Q4 23
11.2x
—
Q1 24
11.0x
—
Q2 24
10.9x
—
Q3 24
10.4x
—
Q4 24
10.3x
—
Q1 25
10.1x
—
Q2 25
9.8x
—
Q3 25
9.6x
—
Q4 25
8.4x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$26M
-$26M
Q2 23
-$20M
-$20M
Q3 23
-$17M
-$17M
Q4 23
-$13M
-$13M
Q1 24
-$32M
-$32M
Q2 24
-$24M
-$24M
Q3 24
-$28M
-$28M
Q4 24
-$14M
-$14M
Q1 25
-$42M
-$42M
Q2 25
-$40M
-$40M
Q3 25
-$42M
-$42M
Q4 25
-$38M
-$38M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$23K
Q2 23
$15K
Q3 23
$100K
Q4 23
$54K
Q1 24
$0
Q2 24
$84K
Q3 24
$96K
Q4 24
$115K
Q1 25
$44K
Q2 25
$141K
Q3 25
$87K
Q4 25
$17K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+26.7%
+10.5%
Q2 23
+27.3%
+3.4%
Q3 23
+29.5%
+0.5%
Q4 23
+30.1%
-0.6%
Q1 24
+9.2%
+13.5%
Q2 24
+3.4%
+30.6%
Q3 24
+20.9%
+24.4%
Q4 24
+4.4%
+36.9%
Q1 25
+7.8%
+28.4%
Q2 25
+10.8%
+37.7%
Q3 25
+9.0%
+28.3%
Q4 25
+54.0%
+9.1%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$2M
13.3%
Q2 23
$2M
10.5%
Q3 23
$2M
10.7%
Q4 23
$3M
11.1%
Q1 24
$3M
14.7%
Q2 24
$4M
16.3%
Q3 24
$3M
13.8%
Q4 24
$3M
13.4%
Q1 25
$3M
15.2%
Q2 25
$3M
11.3%
Q3 25
$3M
11.0%
Q4 25
$3M
8.3%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$12M
$24M
Q2 23
$12M
$22M
Q3 23
$10M
$22M
Q4 23
$11M
$25M
Q1 24
$15M
$27M
Q2 24
$15M
$30M
Q3 24
$11M
$29M
Q4 24
$15M
—
Q1 25
$20M
$35M
Q2 25
$19M
$43M
Q3 25
$14M
$38M
Q4 25
$14M
$39M
marketcaparena.com
Revenue Segments
Jelmyto
Quarter
Jelmyto
Q1 23
$17M
Q2 23
$21M
Q1 24
$19M
Q2 24
$22M
Q3 24
$25M
Q1 25
$20M
Q2 25
$24M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$37M
$29M
$65M
Q2 23
$20M
$27M
$47M
Q3 23
$119M
$28M
$147M
Q4 23
$96M
$42M
$138M
Q1 24
$132M
$33M
$165M
Q2 24
$220M
$21M
$241M
Q3 24
$125M
$125M
$250M
Q4 24
$172M
$65M
$237M
Q1 25
$104M
$92M
$196M
Q2 25
$93M
$64M
$157M
Q3 25
$90M
$37M
$127M
Q4 25
$111M
$10M
$120M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
23M
+0.8%
Q2 23
23M
+0.8%
Q3 23
32M
+37.7%
Q4 23
36M
+11.9%
Q1 24
33M
-7.7%
Q2 24
37M
+10.3%
Q3 24
43M
+17.1%
Q4 24
47M
+9.1%
Q1 25
47M
+0.8%
Q2 25
48M
+0.7%
Q3 25
48M
+0.7%
Q4 25
49M
+2.4%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
—
—
FY 17
$194K
42
FY 18
$14K
78
FY 19
$104
173
FY 20
$63K
187
FY 21
$246K
195
FY 22
$322K
200
FY 23
$412K
201
FY 24
$385K
235
FY 25
$549
200K
marketcaparena.com